References
- Agusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J 2016; 47(2):410–419.
- Greulich T, Nell C, Hohmann D, Grebe M, Janciauskiene S, Koczulla AR, Vogelmeier CF. The prevalence of diagnosed α1-antitrypsin deficiency and its comorbidities: results from a large population-based database. Eur Respir J 2017; 49(1). pii:1600154.
- Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J 2015; 45(5):1446–1462.
- Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009; 374(9691):733–743.
- Aliberti S, Lonni S, Dore S, McDonnell MJ, Goeminne PC, Dimakou K, et al. Clinical phenotypes in adult patients with bronchiectasis. Eur Respir J 2016; 47(4):1113–1122.
- Quint JK, Millett ER, Joshi M, Navaratnam V, Thomas SL, Hurst JR, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J 2016; 47(1):186–193.
- Soriano JB, Rodríguez-Roisin R. Chronic obstructive pulmonary disease overview: epidemiology, risk factors, and clinical presentation. Proc Am Thorac Soc 2011; 8(4):363–367.
- Greulich T, Vogelmeier CF. Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis. Ther Adv Respir Dis 2016; 10(1):72–84.
- Hurst JR, Elborn JS, De Soyza A; BRONCH-UK consortium. COPD-bronchiectasis overlap syndrome. Eur Respir J 2015; 45(2):310–313.
- McDonnell MJ, Aliberti S, Goeminne PC, Restrepo MI, Finch S, Pesci A, et al. Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. Lancet Respir Med 2016; 4(12):969–979.
- Barnes NC, Sharma R, Lettis S, Calverley PM. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J 2016; 47(5):1374–8132.
- Stockley RA. Antitrypsin deficiency assessment and programme for treatment (ADAPT): the United Kingdom registry. COPD 2015; 12(Suppl. 1):63–68.
- Fähndrich S, Herr C, Greulich T, Seibert M, Lepper PM, Bernhard N, et al. Sex differences in alpha-1-antitrypsin deficiency lung disease-analysis from the German registry. COPD 2015; 12(Suppl. 1):58–62.
- Morélot-Panzini C, Gilet H, Aguilaniu B, Devillier P, Didier A, Perez T, et al. Real-life assessment of the multidimensional nature of dyspnoea in COPD outpatients. Eur Respir J 2016; 47(6):1668–1679.
- Agustí A, Rennard S, Edwards LD, MacNee W, Wouters E, Miller B, et al. Clinical and prognostic heterogeneity of C and D GOLD groups. Eur Respir J 2015; 46(1):250–254.
- Chalmers JD, McDonnell MJ, Rutherford R, Davidson J, Finch S, Crichton M, et al. The generalizability of bronchiectasis randomized controlled trials: a multicentre cohort study. Respir Med 2016; 112:51–58.